SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group Q1 Margin Compression Reinforces Bearish Profitability Narratives
CSPC Pharmaceutical Group (SEHK:1093) has kicked off 2026 with Q1 revenue of C¥6.5b and basic EPS of C¥0.075, setting the tone for how its earnings story may evolve from here. Over recent quarters the company has seen quarterly revenue move between C¥6.1b and C¥7.0b, while basic EPS has ranged from about C¥0.033 to C¥0.129, giving investors a clear view of how the topline and per share earnings have tracked together. With trailing net profit margins easing over the last year, this latest...